This new knowledge improves our understanding of the renal mechanisms of blood pressure regulation as well as Ang II-induced hypertension and suggests that both AT1a receptors and NHE3 may be potential therapeutic targets in treating hypertension in humans. This evidence concerns the gene SLC9A3 and hypertensive disorder.